Gelonghui June 23 丨Deqi Pharmaceutical-B (06996.HK) announced that after the Sydney Bellberry Human Research Ethics Committee (“HREC”) approved the ATG-018 phase I clinical trial (ATRIUM trial) application for the treatment of patients with advanced solid tumors and hematologic malignancies, the Australian Medicines Agency (“TGA”) also issued a clinical trial notice confirming the project on June 22, 2022 (“CTN”).
德琪医药-B(06996.HK)：澳大利亚药品管理局确认ATG-018用于治疗晚期实体瘤及血液系统恶性肿瘤的I期临床试验的临床试验通知
Deqi Pharmaceutical-B (06996.HK): Australian Medicines Administration Confirms ATG-018 Clinical Trial Notice for Phase I Clinical Trials to Treat Advanced Solid Tumors and Hematologic Malignancies
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Statement
This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.
Write a comment
0 0 0
LikeLoveLaughing CryRespectEmmSadAngry
Tap to Select a Mood
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
Use the share button in your browser
to share the page with your friends
Tap here to share
No comments yet. Write one.